Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.
2.

A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.

Oberhänsli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer JC, Baeriswyl G, Goy JJ, Cook S.

Arch Cardiovasc Dis. 2012 Nov;105(11):587-92. doi: 10.1016/j.acvd.2012.06.001. Epub 2012 Oct 4.

3.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
4.

A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel.

Sambu N, Radhakrishnan A, Curzen N.

J Cardiovasc Pharmacol. 2012 Dec;60(6):495-501. doi: 10.1097/FJC.0b013e31826f36bc.

PMID:
23232787
6.

Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography.

Srimahachota S, Rojnuckarin P, Udayachalerm W, Buddhari W, Chaipromprasit J, Lertsuwunseri V, Akkawat B, Jirapattrathamrong S.

J Med Assoc Thai. 2012 Dec;95(12):1495-500.

PMID:
23390778
7.

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF.

Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.

8.

Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study.

Di Girolamo G, Czerniuk P, Bertuola R, Keller GA.

Clin Ther. 2010 Jan;32(1):161-70. doi: 10.1016/j.clinthera.2010.01.010.

PMID:
20171421
9.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
10.
11.

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators.

Circulation. 2007 Dec 18;116(25):2923-32. Epub 2007 Dec 3.

12.

Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: a clinical trial.

Müller A, Octavio J, González MY, Contreras J, Méndez G, Portillo M, Valero Z.

Am J Ther. 2010 May-Jun;17(3):351-6. doi: 10.1097/MJT.0b013e3181c15221.

PMID:
20019589
13.

The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.

De Kam PJ, Luo WL, Wenning L, Ratcliffe L, Sisk CM, Royalty J, Radziszewski W, Wagner JA, Lai E.

Platelets. 2014;25(7):480-7. doi: 10.3109/09537104.2013.836747. Epub 2013 Nov 8.

PMID:
24206527
14.

The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.

JACC Cardiovasc Interv. 2008 Dec;1(6):612-9. doi: 10.1016/j.jcin.2008.09.005.

15.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
17.
18.

Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.

Komosa A, Siller-Matula JM, Kowal J, Lesiak M, Siniawski A, Mączyński M, Michalak M, Mularek-Kubzdela T, Grajek S.

Platelets. 2015;26(1):43-7. doi: 10.3109/09537104.2013.877581. Epub 2014 Feb 5.

PMID:
24499166
19.

The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.

Jeong YH, Koh JS, Kang MK, Ahn YJ, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY.

Korean J Intern Med. 2010 Jun;25(2):154-61. doi: 10.3904/kjim.2010.25.2.154. Epub 2010 Jun 1.

Supplemental Content

Support Center